Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer

被引：0
|
作者：
Planjery, S. [1 ]
Mohammed, O. [1 ]
Boppana, M. [1 ]
Thota, N. K. [2 ]
Ravella, V. R. [1 ]
机构：
[1] KIMS Krishna Inst Med Sci KIMS Hosp, Med Oncol, Secunderabad, India
[2] KIMS Krishna Inst Med Sci KIMS Hosp, Hematol & Med Oncol Dept, Secunderabad, India
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.228
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
192P
引用
收藏
页码：S1510 / S1510
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant chemotherapy for epithelial ovarian cancer—role of apoptosis
    Tania Dutta
    Himani Sharma
    Lalit Kumar
    A. K. Dinda
    Sunesh Kumar
    Neerja Bhatla
    Neeta Singh
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 427 - 435
  • [22] Human epididymis protein 4 (HE4) and ovarian cancer prognosis
    Trudel, Dominique
    Tetu, Bernard
    Gregoire, Jean
    Plante, Marie
    Renaud, Marie-Claude
    Bachvarov, Dimcho
    Douville, Pierre
    Bairati, Isabelle
    GYNECOLOGIC ONCOLOGY, 2012, 127 (03) : 511 - 515
  • [23] Diagnostic role of urine human epididymis protein 4 in ovarian cancer
    Hanzek, Antonija
    Siatka, Christian
    Duc, Anne-Cecile E.
    BIOCHEMIA MEDICA, 2024, 34 (03)
  • [24] Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic review of literature
    Plotti, Francesco
    Bartolone, Martina
    Terranova, Corrado
    Luvero, Daniela
    Scaletta, Giuseppe
    Gatti, Alessandra
    Benedetti, Panici Pierluigi
    Angioli, Roberto
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2020, 41 (06) : 889 - 896
  • [25] Multi-parametric FDG PET/MRI as an Early Predictor of Response to Neoadjuvant Chemotherapy in Patients wit Epithelial Ovarian Cancer
    Franceschi, Ana
    Pothuri, Bhavana
    Frey, Melissa
    Chandarana, Hersh
    Jackson, Kimberly
    Friedman, Kent
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [26] Multi-parametric FDG PET/MRI as an early predictor of response to neoadjuvant chemotherapy in patients with epithelial ovarian cancer.
    Frey, Melissa Kristen
    Sawaged, Zacharia
    Franceschi, Ana M.
    Friedman, Kent P.
    Lutz, Kathleen
    Curtin, John Patrick
    Blank, Stephanie V.
    Pothuri, Bhavana
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Pathological response of ovarian cancer to neoadjuvant chemotherapy
    Ivantsov, Alexandr O.
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (06)
  • [28] PROGNOSTIC ROLE OF PATHOLOGICAL CHEMOTHERAPY RESPONSE SCORE IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER
    Setton, Ariella Jakobson
    Levin, Gabriel
    Raban, Oded
    Sabah, Gad
    Tsoref, Daliah
    From, Anat
    Perri, Tamar
    Eitan, Ram
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A142 - A143
  • [29] Methylation: a predictor of chemotherapy response in ovarian cancer?
    A. Ahluwalia
    P. Yan
    T.H.-M. Huang
    K.P. Nephew
    Nature Genetics, 2001, 27 (Suppl 4) : 38 - 38
  • [30] The Human epididymis protein 4 (HE4) as a marker of ovarian cancer recurrence
    Michienzi, Simona
    Falzarano, Renato
    Viggiani, Valentina
    Rossini, Daniele
    Longo, Flavia
    Anastasi, Emanuela
    BIOCHIMICA CLINICA, 2013, 37 (03) : 195 - 199
12345